Leaflet: information for the user
Lenalidomida TecniGen 2.5 mg hard capsules EFG
Lenalidomida TecniGen 5 mg hard capsules EFG
Lenalidomida TecniGen 7.5 mg hard capsules EFG
Lenalidomida TecniGen 10 mg hard capsules EFG
Lenalidomida TecniGen 15 mg hard capsules EFG
Lenalidomida TecniGen 20 mg hard capsules EFG
Lenalidomida TecniGen 25 mg hard capsules EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
-Keep this leaflet, as you may need to read it again.
-If you have any questions, consult your doctor or pharmacist.
-This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
-If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. See section 4.
1. What Lenalidomida TecniGen is and what it is used for
2. What you need to know before taking Lenalidomida TecniGen
3. How to take Lenalidomida TecniGen
4. Possible side effects
5. Storage of Lenalidomida TecniGen
6. Contents of the pack and additional information
What is Lenalidomida TecniGen
Lenalidomida TecniGen contains the active ingredient “lenalidomida”. This medication belongs to a group of medications that affect how the immune system functions.
What is Lenalidomida TecniGen used for
Lenalidomida is used in adults for:
Multiple Myeloma
Multiple myeloma is a type of cancer that affects a specific type of white blood cell in the blood, called plasma cells. These cells accumulate in the bone marrow and multiply, becoming uncontrolled. This can damage bones and kidneys.
Multiple myeloma generally does not have a cure. However, the symptoms and signs can be significantly reduced or disappear for a period of time. This is called “remission”.
Multiple Myeloma Newly Diagnosed: in patients who have undergone a bone marrow transplant
Lenalidomida is used as maintenance treatment after recovering adequately from a bone marrow transplant.
Multiple Myeloma Newly Diagnosed: in patients who cannot be treated with a bone marrow transplant
Lenalidomida is taken with other medications, including:
You will take these medications when starting treatment and then continue taking lenalidomida alone.
If you are 75 years or older or have moderate to severe kidney problems, your doctor will closely monitor you before starting treatment.
Multiple Myeloma: in previously treated patients
Lenalidomida is taken with an anti-inflammatory called “dexametasona”.
Lenalidomida can slow the progression of multiple myeloma symptoms. It has also been shown to delay the recurrence of multiple myeloma after treatment.
Myelodysplastic Syndromes (MDS)
MDS are a group of many different blood and bone marrow diseases. Blood cells become abnormal and do not function correctly. Patients may experience a variety of symptoms, including low red blood cell count (anemia), the need for blood transfusions, and the risk of infection.
Lenalidomida is used to treat adult patients diagnosed with MDS, when the following points are applicable:
• you need periodic blood transfusions to treat low red blood cell levels (“anemia-dependent transfusions”)
• you have a bone marrow cell anomaly called “isolated 5q deletion cytogenetic anomaly”. This means your body does not produce enough healthy blood cells
• other treatments you have used previously are not suitable or do not work well enough.
Lenalidomida can increase the number of healthy red blood cells produced by the body by reducing the number of abnormal cells:
• this can reduce the number of blood transfusions needed. It may be possible to avoid transfusions.
Mantle Cell Lymphoma (MCL)
MCL is a cancer of a part of the immune system (lymphoid tissue). It affects a type of white blood cell in the blood called “B lymphocytes” or B cells. MCL is a disease in which B cells grow uncontrollably and accumulate in lymphoid tissue, bone marrow, or blood.
Lenalidomida is used in monotherapy to treat adult patients who have received previous treatment with other medications.
Follicular Lymphoma (FL)
FL is a slow-growing cancer that affects B lymphocytes. These are a type of white blood cell that helps the body fight infections. When a person has FL, they may store too many of these B lymphocytes in the blood, bone marrow, lymph nodes, and spleen.
Lenalidomida is used with another medication called “rituximab” for the treatment of adult patients who have received previous treatment for follicular lymphoma.
How Lenalidomida TecniGen works
Lenalidomida works by affecting the body's immune system and directly attacking cancer.
It acts in several ways:
You should read the leaflet for all the medicines you are going to take in combination with lenalidomide before starting treatment with this medicine.
Do not take lenalidomide:
If any of these conditions apply to you, do not take lenalidomide. In case of doubt, consult your doctor.
Warnings and precautions
Consult your doctor, pharmacist or nurse before starting to take lenalidomide if:
If any of the above conditions apply to you, inform your doctor, pharmacist or nurse before starting treatment.
Inform your doctor, pharmacist or nurse immediately if you experience:
Analysis and tests
Before starting treatment with lenalidomide and during treatment, you will have regular blood tests, as lenalidomide may cause a decrease in the white blood cells that help fight infections and platelets that participate in blood clotting.
Your doctor will ask you to have a blood test:
You may be evaluated to detect signs of cardiopulmonary problems before and during treatment with lenalidomide.
For patients with SMD who take lenalidomide
If you have SMD, you may be more prone to developing a more advanced disease called acute myeloid leukemia (AML). Additionally, it is unknown how lenalidomide affects your chances of developing AML. Your doctor may perform tests to detect signs that may better predict your chances of developing AML during treatment with lenalidomide.
For patients with MCL who take lenalidomide
Your doctor will ask you to have a blood test:
For patients with LF who take lenalidomide
Your doctor will ask you to have a blood test:
Your doctor may check if you have a high total tumor burden in the body, including the bone marrow. This could lead to a disease in which the tumors break down and produce unusual levels of chemical substances in the blood that, in turn, may cause kidney failure (this disease is called tumour lysis syndrome).
Your doctor may examine you to check if any changes have occurred in your skin, such as red spots or skin rashes.
Your doctor may adjust your lenalidomide dose or interrupt your treatment, depending on the results of your blood tests and your overall condition. If you are a new diagnosis patient, your doctor may also evaluate your treatment based on your age and any other conditions you already have.
Blood donation
You should not donate blood during treatment or for at least 7 days after the end of treatment.
Children and adolescents
The use of lenalidomide is not recommended in children and adolescents under 18 years old.
Older adults and patients with kidney problems
If you are 75 years old or more or have moderate to severe kidney problems, your doctor will carefully examine you before starting treatment.
Other medicines and Lenalidomide TecniGen
Inform your doctor or nurse if you are taking, have recently taken or may need to take any other medicine. This is because lenalidomide may affect how other medicines work. Additionally, some medicines may affect how lenalidomide works.
Specifically, inform your doctor or nurse if you are taking any of the following medicines:
Pregnancy, breastfeeding and contraception: information for women and men
Pregnancy
Women taking lenalidomide
Men taking lenalidomide
Breastfeeding
You should not breastfeed while taking lenalidomide, as it is unknown whether lenalidomide passes into breast milk.
Contraception
For women taking lenalidomide
Before starting treatment, ask your doctor if you are capable of becoming pregnant, even if you think this is unlikely.
If you can become pregnant
And
For men taking lenalidomide
Lenalidomide passes into human semen. If your partner becomes pregnant or may become pregnant and does not use any effective contraceptive method, you must use condoms during treatment and for at least 7 days after completing treatment, even if you have undergone a vasectomy.
Driving and operating machinery
You should not drive or operate machinery if you feel dizzy, tired, drowsy, have vertigo or blurred vision after taking lenalidomide.
Lenalidomide TecniGen contains lactose
Lenalidomide TecniGen contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medicine.
Lenalidomide TecniGen contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per hard capsule; that is, it is essentially “sodium-free”.
Lenalidomide should be administered by a healthcare professional with experience in the treatment of multiple myeloma, SMD, LCM or LF..
Follow exactly the administration instructions of lenalidomide indicated by your doctor.In case of doubt, consult your doctor or pharmacist.
If you are taking lenalidomide with other medications, you must consult the leaflet of those other medications to obtain additional information on their use and effects.
Treatment cycle
Lenalidomide is taken on certain days during the period of 3 weeks (21 days).
Or
Lenalidomide is taken on certain days during the period of 4 weeks (28 days).
How much lenalidomide to take
Before starting treatment, your doctor will indicate:
How and when to take lenalidomide
Administration of this medication
To remove the capsule from the blister:
Duration of treatment with lenalidomide
Lenalidomide is taken in treatment cycles, each cycle lasting 21 or 28 days (see “Treatment cycle” above). You must continue the treatment cycles until your doctor informs you to stop treatment.
If you take more lenalidomide than you should
If you take more lenalidomide than prescribed, inform your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take lenalidomide
If you forget to take lenalidomide at your usual time and
If you have any other doubts about the use of thismedication, ask your doctororpharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
If you experience any of the following serious side effects, stop taking lenalidomide and seek medical attention immediately, as it may require emergency medical treatment:
Seek immediate medical attention if you notice any of the following serious side effects:
Lenalidomide can reduce the number of white blood cells that fight infections and also the cells in the blood that help to clot the blood (platelets), which can cause bleeding disorders such as nosebleeds and bruises.
Lenalidomide can also cause blood clots in the veins (thrombosis).
Other side effects
It is essential to note that a reduced number of patients may develop other types of cancer, and it is possible that this risk may increase with lenalidomide treatment. Therefore, your doctor must carefully evaluate the benefits and risks of prescribing lenalidomide.
Very common(may affect more than 1 in 10 people):
Side effectscommon(may affect up to 1 in 10 people):
Side effectsinfrequent(may affect up to 1 in 100 people):
Side effects ofunknown frequency(cannot be estimated from available data):
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and blister, after “CAD”. The expiration date is the last day of the month indicated.
Lenalidomida TecniGen 2.5 mg, 5 mg, 7.5 mg hard capsules: store below 30°C.
Lenalidomida TecniGen 10 mg, 15 mg, 20 mg, 25 mg hard capsules: this medication does not require special storage conditions.
Do not use this medication if you observe visible signs of deterioration or signs of improper handling on the packaging.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. In this way, you will help protect the environment.
Composition of Lenalidomida TecniGen
Lenalidomida TecniGen 2.5 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 2.5 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
- capsule coating:gelatin, yellow iron oxide (E172), titanium dioxide (E171), black iron oxide (E172) and brilliant blue FCF (E133).
Lenalidomida TecniGen 5 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 5 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
- capsule coating:gelatin, titanium dioxide (E171) and brilliant blue FCF (E133).
Lenalidomida TecniGen 7.5 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 7.5 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-capsule coating:gelatin, titanium dioxide (E171), black iron oxide (E172), yellow iron oxide (E172) and brilliant blue FCF (E133).
Lenalidomida TecniGen 10 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 10 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-capsule coating:gelatin, titanium dioxide (E171), yellow iron oxide (E172), black iron oxide (E172) and brilliant blue FCF (E133).
Lenalidomida TecniGen 15 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 15 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-capsule coating:gelatin, titanium dioxide (E171) and brilliant blue FCF (E133).
Lenalidomida TecniGen 20 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 20 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-capsule coating:gelatin, titanium dioxide (E171), yellow iron oxide (E172), brilliant blue FCF (E133) and black iron oxide (E172).
Lenalidomida TecniGen 25 mg hard capsules EFG
The active ingredient is lenalidomide. Each capsule contains 25 mg of lenalidomide.
The other components are:
-capsule content:anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
-capsule coating:gelatin and titanium dioxide (E171).
Appearance of the product and contents of the package
Lenalidomida TecniGen 2.5 mg hard capsules EFGare hard capsules of size 4 with a green body and a green cap, 14.3 mm ± 0.3 mm x 5.32 mm.
The capsules are presented in packs of 7 or 21 capsules.
Lenalidomida TecniGen 5 mg hard capsules EFGare hard capsules of size 4 with a blue body and a blue cap, 14.3 mm ± 0.3 mm x 5.32 mm.
The capsules are presented in packs of 7 or 21 capsules.
Lenalidomida TecniGen 7.5 mg hard capsules EFGare hard capsules of size 2 with a grey body and a green cap, 18.0 mm ± 0.3 mm x 6.35 mm.
The capsules are presented in packs of 21 capsules.
Lenalidomida TecniGen 10 mg hard capsules EFGare hard capsules of size 2 with a white body and a green cap, 18.0 mm ± 0.3 mm x 6.35 mm.
The capsules are presented in packs of 7 or 21 capsules.
Lenalidomida TecniGen 15 mg hard capsules EFGare hard capsules of size 0 with a white body and a blue cap, 21.7 mm ± 0.3 mm x 7.64 mm.
The capsules are presented in packs of 7 or 21 capsules.
Lenalidomida TecniGen 20 mg hard capsules EFGare hard capsules of size 0 with a blue body and a green cap, 21.7 mm ± 0.3 mm x 7.64 mm.
The capsules are presented in packs of 21 capsules.
Lenalidomida TecniGen 25 mg hard capsules EFGare hard capsules of size 0 with a white body and a white cap, 24.2 mm ± 0.3 mm x 7.66 mm.
The capsules are presented in packs of 21 capsules.
Only some pack sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Tecnimede España Industria Farmacéutica, S.A.
Avda. de Bruselas, 13, 3º D.
28108 Alcobendas (Madrid)
Spain
Responsible manufacturer
Tecnimede – Sociedade Técnico-Medicinal S.A.
Quinta da Cerca, Caixaria
2565-187 Dois Portos
Portugal
Last review date of this leaflet:April 2022
For more detailed information on this medicine, please visit the website of theSpanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.